Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies, Inc. (NASDAQ: SINT) announced preliminary results of its rights offering, which ended on October 12, 2022, with approximately $4.7 million in total subscriptions. Each right allowed the purchase of one unit for $1,000, which includes one share of Series D Convertible Preferred Stock and two classes of warrants, all convertible to common stock at $0.1510 per share. The offering is expected to close around October 17, 2022, pending conditions. The press release emphasizes the Company’s focus on advanced ceramics for medical applications, including silicon nitride products utilized since 2008.

SINTX Technologies, Inc. (NASDAQ: SINT) has received a production order for silicon nitride components from a global aerospace manufacturer. This follows a rigorous qualification process assessing SINTX's Operational and Quality Management Systems. The company's certified AS9100D manufacturing process enabled it to meet strict customer requirements. SINTX's STX-100 silicon nitride offers high strength and durability, making it ideal for aerospace applications. The company anticipates further orders as it expands in the aerospace market, leveraging its existing capabilities in Salt Lake City.

SINTX Technologies has announced the awarding of four new international patents for antibacterial biomedical implants. These patents, granted in Canada, Australia (two patents), and Japan, enhance SINTX's intellectual property portfolio surrounding silicon nitride, a bioceramic noted for its bacteriostatic properties. The company aims to provide more value to its medical device partners, addressing significant healthcare issues related to infections. SINTX has also expanded through acquisitions, recently incorporating new ceramic materials into its offerings.

SINTX Technologies has received a $275k Phase I grant from the National Institutes of Health (NIH) to develop an antimicrobial trauma device. This 3D printed device will feature a carbon fiber reinforced polyetherketoneketone (PEKK) plate with embedded silicon nitride, enhancing its antibacterial properties. Collaborating with Drexel University and others, SINTX aims to address high infection rates in orthopedic trauma procedures. Successful development may lead to a Phase II award for commercialization. This marks NIH's third grant to SINTX within a year.

SINTX Technologies, Inc. (NASDAQ: SINT) announced a Phase II award of $1.1 million from the U.S. Department of Energy to develop 3D-printed alumina ceramic heat exchangers for HVAC systems. This award follows a successful Phase I effort by the company's subsidiary, Technology Assessment and Transfer (TA&T). The project aims to enhance energy efficiency in heating systems, boasting features such as lighter weight and superior thermal conductivity compared to conventional materials. Collaboration with the University of Cincinnati and Carrier is integral to advancing commercialization efforts.

SINTX Technologies, Inc. (NASDAQ: SINT) has announced the commencement of its rights offering subscription period, which has been extended to October 12, 2022. Each right allows the purchase of one unit at a subscription price of $1,000, including shares of Series D Convertible Preferred Stock and warrants. Maxim Group LLC is appointed as dealer-manager for this offering. The registration statement for this rights offering was declared effective by the SEC on September 23, 2022. Investors are advised to contact their brokers for participation details.

SINTX Technologies, Inc. (NASDAQ: SINT) announced a proposed rights offering aimed at security holders. Stock purchases must be completed by September 21, 2022, to be eligible for the offering. Each security holder will receive one non-transferable subscription right to purchase a unit for $1,000, which includes shares of Series D Convertible Preferred Stock and warrants. The subscription period runs from September 26, 2022, to October 10, 2022, unless extended. Maxim Group LLC is serving as the dealer-manager for the offering.

SINTX Technologies announced a successful 510(k) pre-submission meeting with the FDA regarding their FleX-SN PEEK spine implants. The FDA provided positive feedback on SINTX's regulatory strategies, allowing the company to proceed with its 510(k) filing and commercialization efforts. FleX-SN PEEK aims to enhance bone healing and reduce infection risks in surgical applications. The collaboration with Solvay has strengthened the product's efficacy. The company has been actively expanding its portfolio, including the acquisition of Technology Assessment & Transfer for other ceramic biomaterials.

SINTX Technologies and Oxford Performance Materials have developed a new orthopedic coating using PEKK and silicon nitride. This composite technology aims to address risks associated with metallic implants, such as infection and metal ion exposure. The coating enhances bone integration and resists bacterial adhesion, presenting an innovative solution for implants in orthopedics and dentistry. While the technology is FDA approved for individual components, further testing is underway to secure regulatory approval for the composite coating. Initial industry feedback has been positive, suggesting wide application potential.